Portal de Periódicos da CAPES

Favipiravir: A new and emerging antiviral option in COVID-19

2020; Elsevier BV; Volume: 76; Issue: 4 Linguagem: Inglês

10.1016/j.mjafi.2020.08.004

2213-4743

Umang Agrawal, Reyma Sara Raju, Zarir Udwadia,

Influenza Virus Research Studies

With over 16 million cases reported from across the globe, the SARS-CoV-2, a mere 125 microns in diameter, has left an indelible impact on our world. With the paucity of new drugs to combat this disease, the medical community is in a race to identify repurposed drugs that may be effective against this novel coronavirus. One of the drugs which has recently garnered much attention, especially in India, is an anti-viral drug originally designed for influenza, called favipiravir. In this article, we have tried to provide a comprehensive, evidence-based review of this drug in the context of the present pandemic to elucidate its role in the management of COVID-19.